title: [A case of triple-negative breast cancer responding to multidisciplinary treatment containing bevacizumab].
abstract: We report a case of a 64-year-old woman with Stage IV breast cancer who responded well to chemotherapy containing bevacizumab. She noticed a left breast tumor with acute progression and was diagnosed as having Stage IV, estrogen receptor( ER)(-), progesterone receptor(PgR)(-), human epidermal growth factor receptor 2(HER2)(-)breast cancer (T4cN3cM1[lymph nodes]). She received 5 courses of adriamycin(60mg/m / 2)plus cyclophosphamide(600mg/m2)(AC therapy)and 4 courses of weekly paclitaxel(PTX 90mg/m / 2)plus bevacizumab(AVA 10 mg/m2)as systemic therapy. Computed tomography(CT)and magnetic resonance imaging(MRI)revealed a complete response(CR). After local resection of the breast tumor and radiation to the breast and regional lymph nodes, capecitabine therapy was initiated. Currently, at 5 months after surgery, no new lesion has been detected.
authors.affiliation: Dept. of Gastrointestinal, Breast, and Transplantation Surgery,Hiroshima Prefectural Hospital.
authors.forename: Midori
authors.initials: M
authors.lastname: Noma
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohara
authors.forename: Yuki
authors.initials: Y
authors.lastname: Imaoka
authors.forename: Hirosato
authors.initials: H
authors.lastname: Mashima
authors.forename: Shinori
authors.initials: S
authors.lastname: Mizota
authors.forename: Sho
authors.initials: S
authors.lastname: Okimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Takakura
authors.forename: Koichi
authors.initials: K
authors.lastname: Oishi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kohashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikeda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Fudaba
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Matsugu
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishimoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakahara
authors.forename: Takashi
authors.initials: T
authors.lastname: Urushihara
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Itamoto
authors.forename: Mihoko
authors.initials: M
authors.lastname: Doi
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishisaka
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel